Part 7/10:
This approach aims to disrupt the usual deployment of cancer immunotherapy, and the potential for dramatic improvements in survival rates is notable. In current practice, about half of the patients undergoing surgery for cancer achieve remission, but residual cancer cells can cause recurrence. SURGE’s biodegradable, thermosensitive hydrogel—liquid at room temperature yet gelling at body temperature—is a groundbreaking delivery mechanism. Administered directly at the tumor site, it solidifies, releasing drugs precisely where needed, representing a significant step forward in localized treatment.